New drug combo tested to protect transplanted hearts and kidneys

NCT ID NCT04477629

Recruiting now Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

Summary

This study is testing if adding a drug called belatacept to the usual anti-rejection medications is safe for adults who have just received a heart transplant. The goal is to see if this combination can better protect the new heart from rejection while also helping to preserve the patient's kidney function, which is a common long-term problem. Researchers will carefully monitor 12 participants for serious side effects and signs of organ rejection.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART TRANSPLANTATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Columbia University
ACTIVE_NOT_RECRUITING

New York, New York, 10032, United States
NYU Langone Health
RECRUITING

New York, New York, 10016, United States

Contact Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

HEART TRANSPLANTATION